UPSTREAM BIO, INC. Increase Decrease In Operating Lease Liability
UPSTREAM BIO, INC. (UPB) reported Increase Decrease In Operating Lease Liability of -$315.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- UPSTREAM BIO, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$160.00K.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$155.00K.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$150.00K.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$142.00K, a 847.37% decline year-over-year.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for fiscal 2025 was -$565.00K.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for fiscal 2024 was -$133.00K.
- UPSTREAM BIO, INC. increase decrease in operating lease liability for fiscal 2023 was -$82.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$315.00K 10-Q · filed 2026-08-11 | -$465.00K derived: sum of 3 quarters · filed 2026-08-11 | -$607.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$155.00K 10-Q · filed 2026-05-13 | -$305.00K derived: sum of 2 quarters · filed 2026-05-13 | -$447.00K derived: sum of 3 quarters · filed 2026-05-13 | -$586.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$292.00K derived: sum of 2 quarters · filed 2026-03-26 | -$431.00K derived: sum of 3 quarters · filed 2026-08-11 | -$565.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$281.00K derived: sum of 2 quarters · filed 2026-08-11 | -$415.00K 10-Q · filed 2025-11-05 | -$522.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$273.00K 10-Q · filed 2026-08-11 | -$380.00K derived: sum of 3 quarters · filed 2026-08-11 | -$361.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$134.00K 10-Q · filed 2026-05-13 | -$241.00K derived: sum of 2 quarters · filed 2026-05-13 | -$222.00K derived: sum of 3 quarters · filed 2026-05-13 | -$245.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$88.00K derived: sum of 2 quarters · filed 2026-03-26 | -$111.00K derived: sum of 3 quarters · filed 2026-03-26 | -$133.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.00K derived: sum of 2 quarters · filed 2025-11-05 | -$26.00K 10-Q · filed 2025-11-05 | -$46.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$45.00K 10-Q · filed 2025-08-06 | -$65.00K derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$22.00K 10-Q · filed 2025-05-06 | -$42.00K derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$82.00K 10-K · filed 2025-03-12 | ||
| 2023-09-30 | -$62.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |